Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

56,920 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Relmacabtagene autoleucel (relma-cel) CD19 CAR-T therapy for adults with heavily pretreated relapsed/refractory large B-cell lymphoma in China.
Ying Z, Yang H, Guo Y, Li W, Zou D, Zhou D, Wang Z, Zhang M, Wu J, Liu H, Zhang P, Yang S, Zhou Z, Zheng H, Song Y, Zhu J. Ying Z, et al. Among authors: zhang m, zhang p. Cancer Med. 2021 Feb;10(3):999-1011. doi: 10.1002/cam4.3686. Epub 2020 Dec 31. Cancer Med. 2021. PMID: 33382529 Free PMC article. Clinical Trial.
[Clinical features of rituximab plus chemotherapy as first-line treatment in patients with diffuse large B-cell lymphoma].
Feng J, Wu J, Song Y, Su L, Zhang M, Li W, Hu Y, Zhang X, Gao Y, Niu Z, Feng R, Wang W, Peng J, Ouyang X, Li X, Wu C, Zhang W, Zeng Y, Xiao Z, Liang Y, Zhuang Y, Wang J, Sun Z, Bai H, Cui T. Feng J, et al. Among authors: zhang m, zhang w, zhang x. Zhonghua Xue Ye Xue Za Zhi. 2014 Apr;35(4):309-13. doi: 10.3760/cma.j.issn.0253-2727.2014.04.013. Zhonghua Xue Ye Xue Za Zhi. 2014. PMID: 24759018 Clinical Trial. Chinese.
[A multicenter study of rituximab-based regimen as first-line treatment in patients with follicular lymphoma].
Wu J, Song Y, Su L, Zhang M, Li W, Hu Y, Zhang X, Gao Y, Niu Z, Feng R, Wang W, Peng J, Li X, Ouyang X, Wu C, Zhang W, Zeng Y, Xiao Z, Liang Y, Zhuang Y, Wang J, Sun Z, Bai H, Cui T, Feng J. Wu J, et al. Among authors: zhang m, zhang w, zhang x. Zhonghua Xue Ye Xue Za Zhi. 2014 May;35(5):456-8. doi: 10.3760/cma.j.issn.0253-2727.2014.05.018. Zhonghua Xue Ye Xue Za Zhi. 2014. PMID: 24857221 Chinese. No abstract available.
Effectiveness of gemcitabine, pegaspargase, cisplatin, and dexamethasone (DDGP) combination chemotherapy in the treatment of relapsed/refractory extranodal NK/T cell lymphoma: a retrospective study of 17 patients.
Zhou Z, Li X, Chen C, Li X, Zhang L, Li L, Wang X, Ma W, Fu X, Wu J, Sun Z, Zhang X, Li Z, Yan J, Chang Y, Lu L, Qin B, Li X, Wen J, Zhang M. Zhou Z, et al. Among authors: zhang l, zhang m, zhang x. Ann Hematol. 2014 Nov;93(11):1889-94. doi: 10.1007/s00277-014-2136-7. Epub 2014 Jun 13. Ann Hematol. 2014. PMID: 24923454
DDGP versus SMILE in Newly Diagnosed Advanced Natural Killer/T-Cell Lymphoma: A Randomized Controlled, Multicenter, Open-label Study in China.
Li X, Cui Y, Sun Z, Zhang L, Li L, Wang X, Wu J, Fu X, Ma W, Zhang X, Chang Y, Nan F, Li W, Su L, Wang J, Xue H, Zhang M. Li X, et al. Among authors: zhang l, zhang m, zhang x. Clin Cancer Res. 2016 Nov 1;22(21):5223-5228. doi: 10.1158/1078-0432.CCR-16-0153. Epub 2016 Apr 8. Clin Cancer Res. 2016. PMID: 27060152 Clinical Trial.
Rituximab plus chemotherapy as first-line treatment in Chinese patients with diffuse large B-cell lymphoma in routine practice: a prospective, multicentre, non-interventional study.
Wu J, Song Y, Su L, Xu L, Chen T, Zhao Z, Zhang M, Li W, Hu Y, Zhang X, Gao Y, Niu Z, Feng R, Wang W, Peng J, Li X, Ouyang X, Wu C, Zhang W, Zeng Y, Xiao Z, Liang Y, Zhuang Y, Wang J, Sun Z, Bai H, Cui T, Feng J. Wu J, et al. Among authors: zhang m, zhang w, zhang x. BMC Cancer. 2016 Jul 26;16:537. doi: 10.1186/s12885-016-2523-7. BMC Cancer. 2016. PMID: 27460571 Free PMC article. Clinical Trial.
Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma.
Li X, Cheng Y, Zhang M, Yan J, Li L, Fu X, Zhang X, Chang Y, Sun Z, Yu H, Zhang L, Wang X, Wu J, Li Z, Nan F, Tian L, Li W, Young KH. Li X, et al. Among authors: zhang l, zhang m, zhang x. J Hematol Oncol. 2018 Jan 31;11(1):15. doi: 10.1186/s13045-018-0559-7. J Hematol Oncol. 2018. PMID: 29386072 Free PMC article.
Three-year Follow-up on the Safety and Effectiveness of Rituximab Plus Chemotherapy as First-Line Treatment of Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in Real-World Clinical Settings in China: A Prospective, Multicenter, Noninterventional Study.
Wu JQ, Song YP, Su LP, Zhang MZ, Li W, Hu Y, Zhang XH, Gao YH, Niu ZX, Feng R, Wang W, Peng JW, Li XL, Ouyang XN, Wu CP, Zhang WJ, Zeng Y, Xiao Z, Liang YM, Zhuang YZ, Wang JS, Sun ZM, Bai H, Cui TJ, Feng JF. Wu JQ, et al. Chin Med J (Engl). 2018 Aug 5;131(15):1767-1775. doi: 10.4103/0366-6999.237401. Chin Med J (Engl). 2018. PMID: 30058572 Free PMC article. Clinical Trial.
56,920 results
You have reached the last available page of results. Please see the User Guide for more information.